Glibornuride
From Infogalactic: the planetary knowledge core
![]() |
|
Names | |
---|---|
IUPAC name
1-(6-hydroxy-1,7,7-trimethyl-5-bicyclo[2.2.1]heptanyl)-3-(4-methylphenyl)sulfonylurea
|
|
Identifiers | |
26944-48-9 ![]() |
|
ChemSpider | 16735831 ![]() |
DrugBank | DB08962 ![]() |
EC Number | 248-124-6 |
Jmol 3D model | Interactive image |
KEGG | D02427 ![]() |
MeSH | C073323 |
PubChem | 33649 |
UNII | VP83E7434R ![]() |
|
|
|
|
Properties | |
C18H26N2O4S | |
Molar mass | 366.48 g/mol |
Pharmacology | |
ATC code | A10 |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
Glibornuride (INN) is an anti-diabetic drug from the group of sulfonylureas.[1]
Synthesis

Glibornuride synthesis:[2] See also: U.S. Patent 3,770,761; eidem, U.S. Patent 3,654,357 (to Hoffmann-La Roche).
Gliburnide is an endo-endo derivative made from camphor-3-carboxamode by borohydride reduction (exo approach), followed by Hofmann rearrangement to carbamate, followed by displacement with sodium tosylamide.
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>